Abstract
The aim of this study is to analyze the variations in the incidence of cardiovascular events and mortality rates in patients with non-valvular atrial fibrillation (NVAF) receiving antithrombotic treatment (VKA, NOAC or antiplatelet drugs) between 2013 and 2020. In addition, this study estimates the impact of these variations in the use of healthcare resources and costs in Spain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
